LEO Pharma to acquire gene therapy company Replay
LEO Pharma has signed a definitive agreement for the acquisition of Replay, a gene therapy company that develops treatments for …
Post
-
-
Thinning revenues: inside the $14bn Eliquis patent cliff
Eliquis (apixaban) is one of the most commercially consequential loss-of-exclusivity (LOE) events in recent pharmaceutical history, with patent expiries expected …
-
Chiesi widens rare disease portfolio with $1.9bn KalVista buyout
Chiesi has conducted the largest acquisition in its 90-year history, agreeing to buy KalVista Pharmaceuticals in a deal worth around …
-
Teva signs off $900m Emalex buyout amid strategic pipeline boosting ploy
Teva Pharmaceuticals will acquire neuroscience specialist, Emalex – a move which Teva executive, Evan Lippman, says effectively complements the company’s …
-
EU’s Joint Clinical Assessment system still finding its footing
In April, Ipsen’s Ojemda (tovorafenib) secured European Commission (EC) approval for the treatment of relapsed or refractory paediatric low-grade glioma. …
-
How eSource adoption is saving time and costs in clinical research
Clinical trial sites and sponsors are turning to eSource to ease pressures over costs and unlock efficiencies, with a recent …
-
Ray Therapeutics receives EMA PRIME status for gene therapy
Ray Therapeutics has received priority medicines (PRIME) designation from the European Medicines Agency (EMA) for its RTx-015 gene therapy to …
-
Regeneron Q1 2026 net income falls 10% to $727m
Regeneron Pharmaceuticals has reported GAAP [Generally Accepted Accounting Principles] net income of $727m for the first quarter of 2026 (Q1 2026), …
-
Pfizer protects $6.4bn heart disease blockbuster from generics, for now
Pfizer has successfully warded off three drug manufacturers from placing generics referencing Vyndamax (tafamidis) on the US market, though the …
-
Eli Lilly bets on recombinases in $2.25bn Profluent R&D pact
Eli Lilly is locking down on its rapid expansion strategy with a second deal this week – joining forces with …
-
The strategic investments expanding CDMO capabilities for HPAPIs and ADCs
As oncology pipelines continue to expand and targeted therapies become more sophisticated, contract development and manufacturing organisations (CDMOs) must invest …
-
Novartis’ Q1 sales miss hints at industry’s utilisation of M&A remedies
A weak Q1 for Novartis that was heavily impacted by generics erosion showcases that the billions of dollars being spent …
-
Arcera and Fosun sign MoU for neuroscience innovation
Arcera Life Sciences and Fosun Pharma have signed a memorandum of understanding (MoU) for a strategic long-term collaboration in licensing, …
-
Rocket to sell PRV for $180m to advance gene therapy pipeline
Rocket Pharmaceuticals has signed an agreement to sell its rare paediatric disease priority review voucher (PRV) for $180m to advance …
-
Merck KGaA and Remepy join forces to develop combo drug-digital therapies
Merck KGaA has inked a collaboration deal with Israeli-US startup, Remepy, to explore the therapeutic potential of combination drug and …
